WALTHAM, Mass.--(BUSINESS WIRE)--Dynogen Pharmaceuticals, Inc. announced today that the European Patent Office has allowed two patent applications related to the uses of DDP733 (pumosetrag): the first for the treatment of irritable bowel syndrome with constipation (IBS-c) and the second for the treatment of gastroesophageal reflux disease (GERD). The claims of EP Application No. 02705169.7-1521 are directed to the use of DDP733 for the treatment and prevention of IBS-c, as well as for the treatment of abdominal pain and discomfort associated with IBS-c. The claims of the second allowed application, which issued as EP Patent No. 1256581 on March 28, 2007, are directed to the use of DDP733 for the treatment of GERD.
